What is a Kit in a Box product?<\/a><\/span><\/p>\n\n\n\n The nordicPRO-C6\u2122 biomarker assay quantifies a fragment of type VI collagen generated during collagen formation, serving as a specific marker of active fibrogenesis and extracellular matrix remodeling. Moreover, it targets a type VI collagen-derived bioactive molecule called endotrophin, which has proven pro-fibrotic and pro-inflammatory signaling properties.<\/p>\n\n\n\n This non-invasive assay provides valuable insight into fibrotic processes underlying a wide range of chronic diseases, including those affecting the heart, kidney, lung, intestinal and metabolic systems. By capturing dynamic changes in type VI collagen synthesis, and the release of the dangerous signaling molecule Endotrophin, nordicPRO-C6\u2122 supports disease monitoring, risk assessment, and therapeutic evaluation in clinical and research settings. Used alongside other collagen biomarkers, nordicPRO-C6\u2122 enables a comprehensive assessment of collagen turnover and fibro-inflammatory progression, informing precision-medicine strategies in anti-fibrotic therapy and patient management.<\/p>\n\n\n At Nordic Bioscience, our approach to measurement is rooted in decades of innovation and a deep understanding of fibrosis. As the originators of nordicPRO\u2011C6\u2122, we perfected the biomarker over 15+ years of clinical trials, built on more than 30 years of expertise in extracellular matrix biomarkers. Today, nordicPRO\u2011C6\u2122 is a household name known to ensure you receive data that is both precise and actionable.<\/p>\n\n\n\n As a prognostic biomarker, nordicPRO-C6\u2122 supports patient selection by identifying individuals more likely to experience disease progression or clinical outcomes \u2014 helping enrich trial populations, boost statistical power, and increase the likelihood of success.<\/p>\n\n\n\n NordicPRO-C6\u2122 has demonstrated value in cardiovascular, kidney, lung, and metabolic diseases, predicting disease progression and clinical outcomes (figure outcomes). In Crohn\u2019s disease (CD), patients can be differentiated into endotypes, with elevated levels observed in those with fibrostenotic strictures compared to those with luminal disease.<\/p>\n\n\n\n NordicPRO-C6\u2122 has received a letter of support from the FDA<\/a> encouraging its use to select HFpEF patients with high disease activity for enrollment in clinical trials.<\/p>\n\n\n\n As a pharmacodynamic marker, NordicPRO-C6\u2122 provides a powerful tool for monitoring the efficacy of treatments that lower the risk of an outcome.<\/p>\n\n\n\n NordicPRO-C6\u2122 provides a powerful tool for monitoring treatment efficacy and tracking disease progression over time. Furthermore, it serves as a critical decision-making tool in clinical trials, helping researchers assess treatment impact, understand the mechanism of action, and accelerate drug development.<\/p>\n\n\n\n Clinical trials are a critical and costly step in drug development. Reducing trial size while maintaining robust data is essential for accelerating market entry and managing costs.<\/p>\n\n\n\n NordicPRO\u2011C6\u2122 transforms clinical trial efficiency by enabling precise pre-stratification of patients. By identifying individuals with active fibroblasts who are most likely to respond to treatment, nordicPRO\u2011C6\u2122 helps optimize patient selection, ensuring trials enroll the right participants from the start. This not only enhances trial success rates but also significantly reduces the number of enrollees needed\u2014saving time, resources, and costs while increasing confidence in the therapeutic\u2019s efficacy.<\/p>\n\n\n\n By integrating nordicPRO\u2011C6\u2122 into clinical trial design, drug developers can streamline recruitment, improve study outcomes, and bring innovative fibrosis-targeted therapies to market faster.<\/p>\n\n\n\n Not all patients respond equally to treatment\u2014many experience varying levels of efficacy and safety, while some fail to respond at all. This leads to wasted resources, ineffective care, and increased healthcare costs.<\/p>\n\n\n\n NordicPRO C6\u2122 provides valuable insights into MOA by detecting active fibroblasts, a key process in disease progression and treatment response. By integrating nordicPRO C6\u2122 into clinical trials, researchers gain a deeper understanding of how a drug interacts with fibrotic pathways, supporting data-driven decisions on safety, efficacy, and patient stratification.<\/p>\n\n\n\n Effective drug development requires real-time insights into treatment efficacy and pharmacodynamic effects to ensure therapies are working as intended. Traditional endpoints often fail to capture early dynamic changes in fibrosis, delaying crucial adjustments in clinical strategies.<\/p>\n\n\n\n NordicPRO C6\u2122 changes this by providing a powerful tool to predict treatment response in fibrotic diseases. By measuring active fibroblasts, nordicPRO C6\u2122 helps identify patients who are most likely to benefit from specific therapies.<\/p>\n\n\n\n Nordic Bioscience\u2019s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.<\/em><\/p>\n<\/details>\n\n\n\nKey features and values<\/summary>\n
\n
Description<\/summary>\n
![\"\"](\"https:\/\/www.nordicbioscience.com\/wp-content\/uploads\/2025\/10\/pro-c6-association-mortality-chronic-diseases-1024x591.webp\")
<\/a>We focus on your research needs<\/strong><\/h2>\n\n\n\n
\n
Patient selection for more efficient clinical trials<\/h2>\n\n\n\n
Monitor drug response<\/h2>\n\n\n\n